NCT02630693 2025-11-25
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
Clinical Trials
6 trialsNCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02536742 2024-02-26
PYTHIA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT03628066 2022-04-20
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT02296801 2022-01-13
PALLET
NSABP Foundation Inc
Phase 2 Completed